In the space of just 2 weeks, at the close of 2005 and creeping into 2006, top 20 pharma company Wyeth signed three high-value product deals, potentially totalling over US$1.3 B. Notably, this spree was somewhat unusual for Wyeth, which has typically entered relatively few alliances in comparison with its big pharma counterparts. However, what is striking is that all three of Wyeth's partners are small biotechnology companies. Furthermore, the most recent of its deals, with Trubion Pharmaceuticals, has been signed to develop a biopharmaceutical product, and also involves access to Trubion's technology. This feature reviews Wyeth's recent deal making spree in the context of the industry as a whole.